AASLD Foundation is proud to announce the new Stravitz Visionary Award! This $500,000 flagship research award is one of the most significant investments in hepatology, marking the largest award in AASLD’s history and in the field.

This new $500,000 award signals a transformative step forward in how AASLD Foundation strategically funds innovation, supports researchers, and shapes the future of hepatology.

Presenters review how genomic, trasncriptomic, and other omic technologies can help us understand the causes and inform treatments for MASLD. Experts elaborate on integrative multiomic analyses, genetic subtyping and risk stratification, phenotypic clustering, microbiome analyses, and metabolic and genetic metabolomic profiles as they relate to MASLD.

Speakers delve into the intersections between alcohol-associated liver disease (ALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), focusing on how multimorbidity—such as obesity, diabetes, and cardiovascular disease—complicates diagnosis, management, and prognosis. Experts discuss the shared and unique pathophysiological mechanisms, the role of genetic and behavioral risk factors, and the importance of a multidisciplinary approach to patient care.

Clinician educators and those with an interest in medical education are invited to connect with your fellow educators at this meetup. Gather for an hour of informal networking with other TLM attendees pursuing a clinician educator career path to share with colleagues, get and give support, and learn from your peers. 

HCC and other liver nodules can develop in patients with Fontan-associated liver disease (FALD) and other vascular liver diseases, which may include conditions such as heart failure and Budd-Chiari syndrome. Currently, the Liver Imaging Reporting and Data System (LI-RADS)—a widely used tool for the imaging diagnosis of HCC—cannot be applied to these patients due to insufficient data and the low specificity of imaging in this context. This session provides an overview of cardiac/vascular liver disease and associated HCC risk. Speakers discuss the controversial topic of HCC surveillance in patients without cirrhosis, explore appropriate surveillance strategies for high-risk patients including those with cirrhosis, and address the diagnostic challenges faced by this population.

Presenters explore the latest developments in noninvasive tests (NITs) for diagnosing metabolic dysfunction-associated steatohepatitis (MASH). The session covers the principles, applications, and clinical integration of advanced NITs such as imaging techniques, biomarkers, and emerging tools. Experts focus on how these methods enhance diagnostic accuracy, reduce reliance on invasive liver biopsies, and improve patient care.

Explore the dual role of liver regeneration in the context of hepatic fibrosis. Experts provide a comprehensive discussion of the interplay between liver regeneration and fibrosis with a focus on therapeutic approaches to manage chronic liver disease. Topics include: (1) mechanisms of liver regeneration examining the molecular and cellular processes driving the liver's regenerative capacity; (2) fibrosis progression focused on how dysregulated regeneration can contribute to the accumulation of fibrotic tissue and chronic liver damage; (3) fibrosis regression exploring how effective liver regeneration can reverse fibrotic changes and restore normal liver function; and (4) the therapeutic implications of implementing strategies to modulate liver regeneration for promoting fibrosis resolution while minimizing the risk of further progression.

Discover the latest advances towards a functional cure of HBV infection. Experts present information about the latest clinical and basic studies exploring gene editing therapy, epigenetic modulation such as gene silencing using CRISPR/Cas9, and viral genetic targets such as antisense oligonucleotide (ASO) and small interfering RNA (siRNA). Experts and participants discuss these topics in the context of the prospect of a hepatitis B cure.